Results 11 to 20 of about 54,075 (219)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Biomolecules & Biomedicine, 2022
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin , Denizcan Güven , Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan , Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker , Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç , Abdullah Sakin , Haci Mehmet Türk, Dilek Çağlayan , Şener Cihan, Yusuf Açikgöz , Doğan Uncu   +33 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

EJNMMI Radiopharmacy and Chemistry, 2023
Background Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain.
Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M. Reilly   +4 more
doaj   +1 more source

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

Frontiers in Pharmacology, 2023
Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a small
Huifang Lv, Yunduan He, Caiyun Nie, Feng Du, Xiaobing Chen   +4 more
doaj   +1 more source

Current perspective – Trastuzumab [PDF]

European Journal of Cancer, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Hall, P.S., Cameron, D.A.
openaire   +3 more sources

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

BMC Cancer, 2023
Background Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice.
Yuna Kim, Yoo Jin Bae, Jie-Hyun Kim, Hyunki Kim, Su-Jin Shin, Da Hyun Jung, Hyojin Park   +6 more
doaj   +1 more source

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Scientific Reports, 2021
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal ...
Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim   +3 more
doaj   +1 more source

Trastuzumab

Women's Health, 2005
Breast cancer is a heterogenous disease with several clinical and biologic subtypes. Human epidermal growth factor receptor 2 (HER 2) is overexpressed in approximately 20% of breast cancers. This overexpression is usually due to HER 2 gene amplification, and results in a more aggressive tumor with a worse prognosis.
Ian E, Smith, Susan G, Cross
openaire   +2 more sources

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study

Scientific Reports, 2022
Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease.
Sanji Ali, Jace Hendry, Duc Le, Prosanta K. Mondal, Amer Sami, Haji Chalchal, Kamal Haider, Osama Ahmed, Ali El-Gayed, Philip Wright, Mehrnoosh Pauls, Kate Johnson, Shahid Ahmed   +12 more
doaj   +1 more source

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)

Chinese Medical Journal, 2022
. Background:. Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab
Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu, Yuanyuan Ji, Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association   +6 more
doaj   +1 more source